Fig. 3. A. Proportion of responders* among patients with anemia at baseline. Anemia-evaluable population: patients with hemoglobin concentration of 10.5 g/dL or less at baseline and with a hemoglobin value at week 24. *Treatment responder (hemoglobin): proportion of women with hemoglobin concentrations of 10.5 g/dL or less at pivotal study baseline who achieved an increase of more than 2 g/dL at week 52. Error bars show 95% CI. B. Least squares mean percent change in hemoglobin concentrations with relugolix combination therapy in women with anemia at baseline. Error bars show 95% CI.

Al-Hendy. Long-term Relugolix in Uterine Leiomyomas. Obstet Gynecol 2022.